Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

140P - Pancreaticoduodenectomy versus combined neoadjuvant chemotherapy and pancreaticoduodenectomy: Survival patterns among patients with stage II & III periampullary carcinoma


23 Nov 2019


Poster display session


Tumour Site

Pancreatic Adenocarcinoma


Mai Abdelkader


Annals of Oncology (2019) 30 (suppl_9): ix42-ix67. 10.1093/annonc/mdz422


M. Abdelkader

Author affiliations

  • Medicine, Faculty of Medicine - Suez Canal University, 41111 - Ismailia/EG


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 140P


Periampullary carcinoma accounts for over 30,000 cancer-related deaths per year in the US. The outcome of the disease differs according to the chosen modality of treatment. This study compared the survival rate between patients undergoing pancreaticoduodenectomy alone versus those receiving neoadjuvant chemotherapy before undergoing the surgery in stage II and III periampullary carcinoma.


Using the SEER database, we extracted the data of 868 patients with periampullary carcinoma from 2007 to 2011, aged between 40-79 years old. We selected patients with periampullary carcinomas who underwent pancreaticoduodenectomy alone compared to those received neoadjuvant chemotherapy before the surgery.


The highest 5-year survival rate was observed in patients receiving neoadjuvant chemotherapy followed by pancreaticoduodenectomy (20.1%); especially those of stage II (20.1%). However, we found no significant difference in overall survival regarding the patients' gender or race.Table:


VariablesOverall survivalp-value
Therapy Surgery Combined17.3% 20.1%0.000**
Stage II III20.1% 7.9 %0.000**
Race White Black19.0% 22.7%0.732
Sex Male Female19.3% 19.5%0.388

Highly significant p-value at ≤ 0.001 Combined: neoadjuvant chemotherapy and surgery.


Patients receiving neoadjuvant chemotherapy before pancreaticoduodenectomy had better 5-year overall survival compared to those undergoing pancreaticoduodenectomy alone; especially stage II.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Mai Abdelkader.


Has not received any funding.


The author has declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.